Merck's New Cholesterol Pill: A Game Changer? (2026)

A new experimental pill, enlicitide, has shown remarkable results in lowering cholesterol levels in individuals at high risk of heart attacks despite taking statins. Researchers reported in the New England Journal of Medicine that enlicitide users experienced a 60% reduction in LDL cholesterol over six months. This is a significant improvement compared to other pills that can be added to statins, which only offer a fraction of the same effect. The study, funded by Merck, provides compelling evidence that enlicitide could be a game-changer for those seeking an easier-to-use option for managing high cholesterol. However, it's important to note that the pill must be taken on an empty stomach, and further studies are needed to determine its long-term impact on heart attacks, strokes, and mortality.

Merck's New Cholesterol Pill: A Game Changer? (2026)

References

Top Articles
Latest Posts
Recommended Articles
Article information

Author: Tuan Roob DDS

Last Updated:

Views: 6169

Rating: 4.1 / 5 (42 voted)

Reviews: 81% of readers found this page helpful

Author information

Name: Tuan Roob DDS

Birthday: 1999-11-20

Address: Suite 592 642 Pfannerstill Island, South Keila, LA 74970-3076

Phone: +9617721773649

Job: Marketing Producer

Hobby: Skydiving, Flag Football, Knitting, Running, Lego building, Hunting, Juggling

Introduction: My name is Tuan Roob DDS, I am a friendly, good, energetic, faithful, fantastic, gentle, enchanting person who loves writing and wants to share my knowledge and understanding with you.